主页 > 医学文档 >
【medical-news】卵巢癌复发患者联合使用托泊替康
"Combination therapies," lead investigator Dr. Jalid Sehouli told Reuters Health, "were associated with higher toxicity, but progression-free survival and overall survival were not significantly different."
Dr. Sehouli, of Humboldt University in Berlin, and colleagues explain in their paper that although topotecan monotherapy is an established treatment, there was evidence to suggest that combination therapy may provide better results.
To investigate further, the researchers studied 502 women in whom ovarian cancer recurred following primary surgery and platinum-based chemotherapy. They were randomized to receive either topotecan alone or in combination with etoposide or gemcitabine.
Median overall survival was not significantly different among the groups: 17.2 months with topotecan alone, 17.8 months with the etoposide combination and 15.2 months with the gemcitabine combination. There were no differences in either median progression-free survival or objective response rates.
The researchers note that the incidence of thrombocytopenia was lower with monotherapy (13.5%) than with the etoposide combination (21.5%) or gemcitabine combination (31.3%), and they conclude that combination therapy increases toxicity and does not provide a survival advantage.
"Based on our results," Dr. Sehouli warns, "physicians should not harm their patients with such combination regimens."
J Clin Oncol 2008;26:3176-3182. [标签:content1][标签:content2]
阅读本文的人还阅读：
作者:admin@医学,生命科学 2011-08-06 17:14
医学,生命科学网